Cas:13440-19-2 (3aR,5R,6S,6aR)-5-[(3R)-1,4-dioxaspiro[4.5]decan-3-yl]-6-methoxyspiro[3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole-2,1′-cyclohexane] manufacturer & supplier

We serve Chemical Name:(3aR,5R,6S,6aR)-5-[(3R)-1,4-dioxaspiro[4.5]decan-3-yl]-6-methoxyspiro[3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole-2,1′-cyclohexane] CAS:13440-19-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(3aR,5R,6S,6aR)-5-[(3R)-1,4-dioxaspiro[4.5]decan-3-yl]-6-methoxyspiro[3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole-2,1'-cyclohexane]

Chemical Name:(3aR,5R,6S,6aR)-5-[(3R)-1,4-dioxaspiro[4.5]decan-3-yl]-6-methoxyspiro[3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole-2,1′-cyclohexane]
CAS.NO:13440-19-2
Synonyms:1,2:5,6-DI-O-CYCLOHEXYLIDENE-3-O-METHYL-a-D-GLUCOFURANOSE
Molecular Formula:C19H30O6
Molecular Weight:354.43800
HS Code:

Physical and Chemical Properties:
Melting point:35-38ºC
Boiling point:465.5ºC at 760mmHg
Density:1.23g/cm3
Index of Refraction:1.539
PSA:55.38000
Exact Mass:354.20400
LogP:2.87790

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,2:5,6-DI-O-CYCLOHEXYLIDENE-3-O-METHYL-a-D-GLUCOFURANOSE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2:5,6-DI-O-CYCLOHEXYLIDENE-3-O-METHYL-a-D-GLUCOFURANOSE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2:5,6-DI-O-CYCLOHEXYLIDENE-3-O-METHYL-a-D-GLUCOFURANOSE Use and application,1,2:5,6-DI-O-CYCLOHEXYLIDENE-3-O-METHYL-a-D-GLUCOFURANOSE technical grade,usp/ep/jp grade.


Related News: Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is a chronic and complex disease with a variety of clinical manifestations that can impact many organs and can cause a range of symptoms including pain, rashes, fatigue, swelling in joints and fevers. 4-Pyridinecarboxamide, 2,6-dichloro-N-[2-(2-chlorophenoxy)ethyl]- manufacturers In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis. methyl (5S,7aR,8S)-1-bromo-5-hydroxy-3-methoxy-5,6,7,7a,8,9-hexahydrophenanthro[4,5-bcd]furan-8-carboxylate suppliers The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus. 5-methoxy-3-(5-methyl-2-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2(3H)-one vendor & factory.